CLAIMS

What is claimed is:

1. Use of Compound A, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating epileptic encephalopathy in a pediatric subject,

wherein Compound A is N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.

2. The use according to Claim 1, wherein the epileptic encephalopathy is KCNQ2 epileptic encephalopathy.

3. Compound A that is N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.

4. A pharmaceutically acceptable salt of N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide.

5. A pharmaceutical composition comprising N-(1-(tert-butyl)-6-cyano-4,7-difluoro-1H-benzo[d]imidazol-2-yl)-3,3-dimethylbutanamide or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.